Haleon Pakistan Limited Stock price

Equities

HALEON

PK0112101016

Pharmaceuticals

End-of-day quote Pakistan S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
184 PKR +1.43% Intraday chart for Haleon Pakistan Limited -2.13% +8.87%
Sales 2021 24.16B 86.89M Sales 2022 27.51B 98.92M Capitalization 19.19B 68.99M
Net income 2021 2.13B 7.67M Net income 2022 325M 1.17M EV / Sales 2021 1.04 x
Net cash position 2021 3.09B 11.1M Net cash position 2022 3.28B 11.8M EV / Sales 2022 0.58 x
P/E ratio 2021
13.2 x
P/E ratio 2022
59 x
Employees 478
Yield 2021 *
-
Yield 2022
-
Free-Float 14.2%
More Fundamentals * Assessed data
Dynamic Chart
Haleon Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Haleon Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Haleon Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Haleon Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Unilever Looking to Reposition Portfolio After GSK Consumer Healthcare Approach -- Update DJ
Unilever Looking to Reposition Portfolio Into Higher Growth Categories DJ
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Glaxosmithkline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
GlaxoSmithkline Consumer Healthcare Pakistan Limited Announces Change of Chief Executive Officer CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Recommends Cash Dividend CI
Glaxosmithkline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2020 CI
More news
1 day+1.43%
1 week-2.13%
Current month-13.72%
1 month-13.98%
3 months+10.03%
6 months+28.36%
Current year+8.87%
More quotes
1 week
180.00
Extreme 180
185.50
1 month
180.00
Extreme 180
213.99
Current year
179.00
Extreme 179
225.00
1 year
120.00
Extreme 120
225.00
3 years
120.00
Extreme 120
303.96
5 years
120.00
Extreme 120
347.00
10 years
65.05
Extreme 65.0548
529.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 21-03-31
Director of Finance/CFO - 14-12-31
Investor Relations Contact - 20-05-30
Members of the board TitleAgeSince
Director/Board Member - 21-03-02
Director/Board Member - 16-06-22
Chief Executive Officer - 21-03-31
More insiders
Date Price Change Volume
24-03-27 184 +1.43% 4,600
24-03-26 181.4 -0.34% 3,500
24-03-25 182 -1.35% 1,200
24-03-22 184.5 -0.75% 1,500
24-03-21 185.9 -1.12% 2,600

End-of-day quote Pakistan S.E., March 26, 2024

More quotes
Haleon Pakistan Limited, formerly Glaxosmithkline Consumer Healthcare Pakistan Limited, is a Pakistan-based healthcare company. The Company's product portfolio consists of five categories, namely oral health, pain relief, respiratory health, digestive health and other, and vitamins, minerals and supplements (VMS). Its geographical segment consists of North America; Europe, Middle East & Africa (EMEA) and Latin America (LatAm), and Asia-Pacific (APAC). The Brands under Oral Health include Sensodyne, Parodontax, Polident, and Biotene. Its Vitamins, Minerals and Supplements offers a portfolio of brands, such as Centrum, a multivitamin and mineral brand; calcium supplements through its Caltrate brand, and vitamin C supplements through Emergen-C. The Brands under Respiratory consists of Otrivin, Theraflu, and Flonase. The Company's Pain Relief product includes Panadol, Voltaren and Advil brands. Its portfolio digestive health brands consists of Eno, Tums, and Fenistil.
More about the company
  1. Stock
  2. Equities
  3. Stock Haleon Pakistan Limited - Pakistan S.E.